US Irritable Bowel Syndrome Treatment Market

The US irritable bowel syndrome treatment market is expected to reach US$ 1,276.21 Mn in 2027 from US$ 586.61 Mn in 2019. The market is estimated to grow with a CAGR of 10.3% from 2020-2027.

The growth of the market is driven by the factors such as, increasing prevalence of irritable bowel syndrome and associated conditions, and increasing numbers of FDA approvals & drug developments. On the other hand, limited number of product availability and treatment inefficiency is likely to restraint the growth of market during the forecast years.

Irritable Bowel Syndrome treatment market is a majorly observed chronic gastrointestinal condition that is caused due to disturbances in bowel habits and abdominal pain. The disease is also known as spastic colon, irritable colon, mucous colitis, and spastic colitis. Irritable bowel syndrome shows symptoms such as abdominal pain, constipation, diarrhea, and cramping.

Health systems across the regions are witnessing considerable growth in the incidence of irritable bowel syndrome. According to data published by International Foundation for Gastrointestinal Disorders, among all irritable bowel syndrome patients about 40% of people have mild IBS, around 35% have moderate IBS, and an estimated have 25% severe IBS. Many people don't recognize IBS symptoms. Certain factors such as food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are some of the risk factors which are causing irritable bowel syndrome. These factors are projected to accelerate the rate of prevalence of irritable bowel syndrome across the globe. For instance, according to a study published on NCBI in 2018, irritable bowel syndrome is estimated to affect around 10% to 16% of the US population each year. Such staggering prevalence of irritable bowel syndrome is likely to boost the US irritable bowel syndrome treatment market during the forecast period.

In order to cope up against irritable bowel syndrome in the country, the companies involved in the drug development for irritable bowel syndrome are taking constructive steps to implement awareness programs with an aim to spread awareness amongst the populations. For instance, in 2018, the collaboration of Allergan PLC and Ironwood launched an Interactive Digital Destination platform to encourage sufferers to get educated and take action. Such initiatives are also anticipated to drive the demand for irritable bowel syndrome treatment market in US.

US Irritable Bowel Syndrome Treatment Market Revenue and Forecast to 2027 (US$ Mn)

Get more information on this report Request Free Sample PDF

US Irritable Bowel Syndrome Treatment Strategic Insights

Strategic insights for the US Irritable Bowel Syndrome Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

US Irritable Bowel Syndrome Treatment Report Scope

US Irritable Bowel Syndrome Treatment Regional Insights

The geographic scope of the US Irritable Bowel Syndrome Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

US Irritable Bowel Syndrome Treatment - Market Segmentation

US Irritable Bowel Syndrome Treatment Market - By Type

• IBS with Diarrhea (IBS-D)
• IBS with Constipation (IBS-C)
• Mixed IBS (IBS-M)

US Irritable Bowel Syndrome Treatment Market - By Product

• Rifaximin
• Eluxadoline
• Linaclotide
• Lubiprostone
• Others

US Irritable Bowel Syndrome Treatment Market - By

Distribution Channel

• Hospitals Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies

Company Profiles

• Ironwood Pharmaceuticals, Inc.
• Allergan Plc.
• Sebela Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Alfasigma S.p.A.
• Astellas Pharma Inc.
• AstraZeneca
• Synthetic Biologics, Inc.
• Bausch + Lomb Incorporated
• Lannett Company Inc.